IMUC EOM Pharmaceutical Holdings Inc. Forecast, Technical & Fundamental Analysis

IMUC's Stochastic Oscillator remains in overbought zone for 9 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 19, 2025. You may want to consider a long position or call options on IMUC as a result. In of 139 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IMUC just turned positive on November 18, 2025. Looking at past instances where IMUC's MACD turned positive, the stock continued to rise in of 70 cases over the following month. The odds of a continued upward trend are .

IMUC moved above its 50-day moving average on November 17, 2025 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for IMUC moved above the 200-day moving average on November 24, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +13 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUC advanced for three days, in of 94 cases, the price rose further within the following month. The odds of a continued upward trend are .

IMUC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.355) is normal, around the industry mean (27.312). P/E Ratio (0.019) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (321.020).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMUC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.